Use of cffDNA to avoid administration of anti‐D to pregnant women when the fetus is RhD‐negative: implementation in the NHS
Authors:
- 21 August 2014
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 122 (12) , 1682-1686
Abstract
Objective: To determine whether a policy of offering cffDNA testing to all RhD‐negative women at about 16 weeks’ gestation to avoid anti‐D administration when the fetus is RhD‐negative could be implemented successfully in the NHS without additional funding.Design: Prospectively planned observational service implementation pilot and notes audit.Setting: Three maternity services in the South West of England.Population: All RhD‐negative women in a 6‐month period.Methods: Prospective, intervention, cross‐sectional observational study, using pre‐intervention data as controls.Main outcome measures: Proportion of suitable women who offered and accepted the test. Accuracy of the cffDNA result as assessed by cord blood group result. Fall in anti‐D doses administered.Results: 529 samples were received; three were unsuitable. The results were reported as RhD‐positive (n = 278), RhD‐negative (n = 185) or inconclusive, treat as positive (n = 63). Cord blood results were available in 502 (95%) and the only incorrect result was one case of a false positive (cffDNA reported as positive, cord blood negative – and so given anti‐D unnecessarily). The notes audit showed that women who declined this service were correctly managed and that anti‐D was not given when the fetus was predicted to be RhD‐negative. The total use of anti‐D doses fell by about 29% which equated to about 35% of RhD‐negative women not receiving anti‐D in their pregnancy unnecessarily.Conclusions: We recommend this service is extended to all UK NHS services.Keywords
This publication has 7 references indexed in Scilit:
- Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHDgenotyping and a review of policy and practiceBMC Pregnancy and Childbirth, 2014
- Noninvasive Single-Exon Fetal RHD Determination in a Routine Screening Program in Early PregnancyObstetrics & Gynecology, 2012
- A nation‐wide fetal RHD screening programme for targeted antenatal and postnatal anti‐DISBT Science Series, 2012
- Report of the first nationally implemented clinical routine screening for fetal RHD in D− pregnant women to ascertain the requirement for antenatal RhD prophylaxisTransfusion, 2011
- Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility studyBMJ, 2008
- Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetalRHDgenotyping serviceTransfusion, 2002
- Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal PlasmaNew England Journal of Medicine, 1998